文献速递淋巴瘤造血干细胞移植与细胞治疗

PD-1阻断后异基因移植治疗经典霍奇金淋巴瘤

Allogeneic transplantation after PD-1 blockade for classic Hodgkin lymphoma.
PubMed 文献 · Leukemia · 2021-03-03

该回顾性队列纳入209例PD-1阻断后接受异基因造血细胞移植的经典霍奇金淋巴瘤患者,中位随访24个月,2年非复发死亡率14%、复发率18%,2年GVHD无复发生存47%、无进展生存69%、总生存82%。多变量分析显示PD-1至移植间隔较长与严重急性GVHD较少相关,移植后环磷酰胺为基础的GVHD预防可显著改善PFS和GRFS。

要点

  • 2年总生存82%、无进展生存69%,非复发死亡14%、复发18%
  • 180天3-4级急性GVHD累积发生率15%,2年慢性GVHD为34%
  • 以PTCy为基础的GVHD预防与PFS和GRFS显著改善相关

核心结论

  • PD-1阻断后异基因移植可行,以PTCy为基础的GVHD预防可能为该人群最佳移植策略。

研究设计与样本

  • 回顾性队列研究,纳入209例PD-1阻断后接受异基因造血细胞移植的经典霍奇金淋巴瘤患者。
  • 存活者中位随访24个月。

主要发现

  • 2年非复发死亡累积发生率为14%,复发累积发生率为18%。
  • 2年GVHD无复发生存为47%,无进展生存为69%,总生存为82%。
  • 180天3-4级急性GVHD累积发生率为15%,2年慢性GVHD累积发生率为34%。
  • 多变量分析中,PD-1至移植间隔较长与严重急性GVHD较少相关。
  • PD-1与移植间额外治疗与更高复发风险相关。

关键数值与推荐

  • 以PTCy为基础的GVHD预防与PFS和GRFS显著改善相关。

临床怎么用

  • 在等待前瞻性临床试验期间,可考虑将以PTCy为基础的GVHD预防作为该人群的移植策略。

局限性

  • 为回顾性队列设计,相关结论尚需前瞻性临床试验验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Anti-PD-1 monoclonal antibodies yield high response rates in patients with relapsed/refractory classic Hodgkin lymphoma (cHL), but most patients will eventually progress. Allogeneic hematopoietic cell transplantation (alloHCT) after PD-1 blockade may be associated with increased toxicity, raising challenging questions about the role, timing, and optimal method of transplantation in this setting. To address these questions, we assembled a retrospective cohort of 209 cHL patients who underwent alloHCT after PD-1 blockade. With a median follow-up among survivors of 24 months, the 2-year cumulative incidences (CIs) of non-relapse mortality and relapse were 14 and 18%, respectively; the 2-year graft-versus-host disease (GVHD) and relapse-free survival (GRFS), progression-free survival (PFS), and overall survival were 47%, 69%, and 82%, respectively. The 180-day CI of grade 3-4 acute GVHD was 15%, while the 2-year CI of chronic GVHD was 34%. In multivariable analyses, a longer interval from PD-1 to alloHCT was associated with less frequent severe acute GVHD, while additional treatment between PD-1 and alloHCT was associated with a higher risk of relapse. Notably, post-transplant cyclophosphamide (PTCy)-based GVHD prophylaxis was associated with significant improvements in PFS and GRFS. While awaiting prospective clinical trials, PTCy-based GVHD prophylaxis may be considered the optimal transplantation strategy for this patient population.

来源:Leukemia,查看原文。版权归原作者所有。

引用

  1. Merryman RW, Castagna L, Giordano L, et al. Allogeneic transplantation after PD-1 blockade for classic Hodgkin lymphoma. Leukemia. 2021. PMID: 33658659. doi:10.1038/s41375-021-01193-6

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。